Register entry
PF PRISM CV
- Registered sites
- 0
- Active NDC listings
- 0
- Live patents
- 59
- Exclusivities
- 3
- Countries
- 0
Exclusivity
Patents and exclusivities
59| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 7767678 | BOSULIFbosutinib monohydrate | substance, product | Nov 2026 |
| 7825137 | XALKORIcrizotinib | use | May 2027 |
| 7767678*PED | BOSULIFbosutinib monohydrate | use | May 2027 |
| 8269040 | PRISTIQdesvenlafaxine succinate | substance | Jul 2027 |
| 8975242 | TYGACILtigecycline | product | Oct 2028 |
| 7879828 | TYGACILtigecycline | product | Feb 2029 |
| 7858643 | XALKORIcrizotinib | substance, product | Oct 2029 |
| 8217057 | XALKORIcrizotinib | substance, product | Nov 2029 |
| 8372995 | TYGACILtigecycline | product | Oct 2030 |
| 8791140 | INLYTAaxitinib | substance | Dec 2030 |
| 8791140*PED | INLYTAaxitinib | use | Jun 2031 |
| 8791097 | TORISELtemsirolimus | use | May 2032 |
| 8791097*PED | TORISELtemsirolimus | use | Nov 2032 |
| 11103497 | BOSULIFbosutinib monohydrate | use | Feb 2034 |
| 11103497*PED | BOSULIFbosutinib monohydrate | use | Aug 2034 |
| 10570202 | INLYTAaxitinib | use | Feb 2035 |
| 12534530 | INLYTAaxitinib | use | Feb 2035 |
| 10570202*PED | INLYTAaxitinib | use | Aug 2035 |
| 12534530*PED | INLYTAaxitinib | use | Aug 2035 |
| 10869924 | INLYTAaxitinib | use | Jan 2037 |
| 10869924*PED | INLYTAaxitinib | use | Jul 2037 |
| Product | Exclusivity | Until |
|---|---|---|
| BOSULIFBOSUTINIB MONOHYDRATE | PED Paediatric | Mar 2031 |
| XALKORICRIZOTINIB | ODE-407 Orphan drug | Jul 2029 |
| XELJANZTOFACITINIB CITRATE | PED Paediatric | Aug 2028 |
Enquiry
Common questions
- Is PF PRISM CV FDA approved?
- PF PRISM CV holds no registered establishment of its own; it appears here on its Orange Book patents.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.